Medina, Jesus R. published the artcileStructure-Based Design of Potent and Selective 3-Phosphoinositide-Dependent Kinase-1 (PDK1) Inhibitors, Category: pyrimidines, the publication is Journal of Medicinal Chemistry (2011), 54(6), 1871-1895, database is CAplus and MEDLINE.
Phosphoinositide-dependent protein kinase-1 (PDK1) is a master regulator of the AGC family of kinases and an integral component of the PI3K/AKT/mTOR pathway. As this pathway is among the most commonly deregulated across all cancers, a selective inhibitor of PDK1 might have utility as an anticancer agent. Herein, the lead optimization of compound I (R1 = R2 = H) toward highly potent and selective PDK1 inhibitors via a structure-based design strategy is described. A series of (amino)(aminopyrimidinyl)indazoles I (R1 = H, Me, Et; R2 = Me, i-Pr, PhNH, 1-piperidinyl, etc.) was synthesized, and the inhibiting activity of the products towards PDK1 was studied. The most potent and selective inhibitors, e.g. I [R1 = Me; R2 = (3S,6R)-3-(cyclohexylaminocarbonyl)-6-methyl-1-piperidinyl], demonstrated submicromolar activity as measured by inhibition of phosphorylation of PDK1 substrates as well as antiproliferative activity against a subset of AML cell lines. In addition, reduction of phosphorylation of PDK1 substrates was demonstrated in vivo in mice bearing OCl-AML2 xenografts. These observations demonstrate the utility of these mols. as tools to further delineate the biol. of PDK1 and the potential pharmacol. uses of a PDK1 inhibitor.
Journal of Medicinal Chemistry published new progress about 56-05-3. 56-05-3 belongs to pyrimidines, auxiliary class Pyrimidine,Chloride,Amine,API, name is 2-Amino-4,6-dichloropyrimidine, and the molecular formula is C4H3Cl2N3, Category: pyrimidines.
Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia